ReviewClinical and experimental immunology2019
Novel approaches for the design, delivery and administration of vaccine technologies.
Review in Clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 121 citations in OpenAlex.
- Recent Advances in Vaccine Development Against Poultry Red Mite (Dermanyssus gallinae): A Literature Review on Native and Recombinant Antigens.Acta parasitologica · 2026Review
- AddaVax-Adjuvanted Inactivated Vaccine Confers Protection Against Listeria monocytogenes Challenge in Mice.Current microbiology · 2026Article
- Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies.Human vaccines & immunotherapeutics · 2025Article
- STING-adjuvanted outer membrane vesicle nanoparticle vaccine against Pseudomonas aeruginosa.JCI insight · 2025Article
- Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines · 2025Review
- Cell-Free Expression of HPV16 Minor Capsid Protein L2 and Its Interaction with S100A10.Protein and peptide letters · 2025Article
- Expression of mastitis causing fibrinogen binding protein of gram positive bacteria in genetically engineered switchgrass and antibodies production in mice.Physiology and molecular biology of plants : an international journal of functional plant biology · 2024Article
- A comprehensive comparison of DNA and RNA vaccines.Advanced drug delivery reviews · 2024Review
- Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen.The Journal of clinical investigation · 2024Article
- Dry and liquid formulations of IBT-V02, a novel multi-component toxoid vaccine, are effective againstFrontiers in immunology · 2024Article
- The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges.Microorganisms · 2023Review
- Advances in vaccines: revolutionizing disease prevention.Scientific reports · 2023Article
- Review
- Synthesis of plant-based, self-adjuvanted, dual antigen specific to Mycobacterium tuberculosis as a novel tuberculosis subunit vaccine that elicits immunogenicity in rabbit.Biotechnology letters · 2023Article
- Computational approaches for molecular characterization and structure-based functional elucidation of a hypothetical protein from Mycobacterium tuberculosis.Genomics & informatics · 2023Article
- Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.Journal of Taibah University Medical Sciences · 2023Review
- A state-of-the-art methodology for high-throughput in silico vaccine discovery against protozoan parasites and exemplified with discovered candidates for Toxoplasma gondii.Scientific reports · 2023Article
- Toxicological Assessments of a Pandemic COVID-19 Vaccine-Demonstrating the Suitability of a Platform Approach for mRNA Vaccines.Vaccines · 2023Article
- Outer Membrane Vesicle-Coated Nanoparticle Vaccine Protects AgainstAdvanced nanobiomed research · 2023Article
- Current Evidence on Vaccinations in Pediatric and Adult Patients with Systemic Autoinflammatory Diseases.Vaccines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
It is easy to argue that vaccine development represents humankind's most important and successful endeavour, such is the impact that vaccination has had on human morbidity and mortality over the last 200 years. During this time the original method of Jenner and Pasteur, i.e. that of injecting live-attenuated or inactivated pathogens, has been developed and supplemented with a wide range of alternative approaches which are now in clinical use or under development. These next-generation technologies have been designed to produce a vaccine that has the effectiveness of the original live-attenuated and inactivated vaccines, but without the associated risks and limitations. Indeed, the method of development has undoubtedly moved away from Pasteur's three Is paradigm (isolate, inactivate, inject) towards an approach of rational design, made possible by improved knowledge of the pathogen-host interaction and the mechanisms of the immune system. These novel vaccines have explored methods for targeted delivery of antigenic material, as well as for the control of release profiles, so that dosing regimens can be matched to the time-lines of immune system stimulation and the realities of health-care delivery in dispersed populations. The methods by which vaccines are administered are also the subject of intense research in the hope that needle and syringe dosing, with all its associated issues regarding risk of injury, cross-infection and patient compliance, can be replaced. This review provides a detailed overview of new vaccine vectors as well as information pertaining to the novel delivery platforms under development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.